KLOR-CON 600 mg/1
potassium chloride · TABLET, FILM COATED, EXTENDED RELEASE · Upsher-Smith Laboratories, LLC
KLOR-CON is a prescription tablet, film coated, extended release containing potassium chloride at 600 mg/1, taken oral. Manufactured by Upsher-Smith Laboratories, LLC.
Key Facts
- Brand Name
- KLOR-CON
- Generic Name
- potassium chloride
- NDC Code (Product)
0245-0835- Manufacturer
- Upsher-Smith Laboratories, LLC
- Strength
- 600 mg/1
- Dosage Form
- TABLET, FILM COATED, EXTENDED RELEASE
- Route
- ORAL
- Marketing Status
- HUMAN PRESCRIPTION DRUG
- Application #
- ANDA218979
- Drug Class
- Increased Large Intestinal Motility [PE]; Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]
- Marketing Start
- 08/15/2025
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Full Prescribing Information
Indications & Usage
1 INDICATIONS AND USAGE Klor-Con is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. KLOR-CON is a potassium salt, indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. ( 1 )
Dosage & Administration
2 DOSAGE AND ADMINISTRATION Monitor serum potassium and adjust dosages accordingly. ( 2.1 ) If serum potassium is less than 2.5 mEq/L, use intravenous potassium instead of oral supplementation. ( 2.1 ) Take with meals and with a glass of water or other liquid. Swallow tablets whole without crushing, chewing or sucking. ( 2.1 ) Treatment of hypokalemia: Doses range from 40 to 100 mEq/day in divided doses. Limit doses to 40 mEq per dose. ( 2.2 ) Prevention of hypokalemia: Typical dose is 20 mEq per day. ( 2.2 ) 2.1 Administration and Monitoring If serum potassium concentration is less than 2.5 mEq/L, use intravenous potassium instead of oral supplementation. Monitoring Monitor serum potassium and adjust dosages accordingly. Monitor serum potassium periodically during maintenance therapy to ensure potassium remains in desired range. The treatment of potassium depletion, particularly in the presence of cardiac disease, renal disease, or acidosis, requires careful attention to acid-base balance, volume status, electrolytes, including magnesium, sodium, chloride, phosphate, and calcium, electrocardiograms, and the clinical status of the patient. Correct volume status, acid-base balance, …
Contraindications
4 CONTRAINDICATIONS Potassium chloride is contraindicated in patients on triamterene and amiloride. Concomitant use with triamterene and amiloride ( 4 )
Drug Interactions
7 DRUG INTERACTIONS Triamterene and amiloride: Concomitant use is contraindicated ( 7.1 ) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7.2 ) Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia ( 7.3 ) 7.1 Triamterene or amiloride Use with triamterene or amiloride can produce severe hyperkalemia. Concomitant use is contraindicated [see Contraindications (4) ] . 7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients on concomitant RAAS inhibitors. 7.3 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.
Adverse Reactions
6 ADVERSE REACTIONS The following adverse reactions have been identified with use of oral potassium salts. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. There have been reports hyperkalemia and of upper and lower gastrointestinal condition including obstruction, bleeding, ulceration, perforation. Skin rash has been reported rarely. The most common adverse reactions are nausea, vomiting, flatulence, abdominal pain/discomfort and diarrhea. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Upsher-Smith Laboratories, LLC at 1-855-899-9180 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Frequently Asked Questions
What is KLOR-CON used for?
KLOR-CON contains potassium chloride. It is a tablet, film coated, extended release taken oral. Consult your doctor for specific uses.
Is KLOR-CON a controlled substance?
KLOR-CON is not classified as a controlled substance by the DEA.
What is the generic name for KLOR-CON?
The generic name for KLOR-CON is potassium chloride. There are 12 other brand versions of potassium chloride.
What is the NDC code for KLOR-CON 600 mg/1?
The NDC (National Drug Code) for KLOR-CON 600 mg/1 is 0245-0835, listed by Upsher-Smith Laboratories, LLC.
Other Potassium Brands
See all →- potassium chloride750 mg/172603-337
- POTASSIUM CHLORIDE750 mg/172789-057
- Potassium Chloride20 meq/182804-075
- Potassium Chloride1500 mg/10904-7293
- POTASSIUM CHLORIDE40 meq/30mL0904-7462
- Potassium Chloride400 meq/1000mL0990-7077
- POKONZA.75 g/.79g15370-305
- Potassium Chloride750 mg/142806-423
- Potassium Chloride20 meq/143386-917
- Potassium Chloride10 meq/150090-6635
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)